Point72 Asset Management
AVDL

Point72 Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Point72 Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,200
Closed -$435K – 3773
2025
Q4 		$435K Hold
20,200
– – ﹤0.01% 3304
2025
Q3 		$308K Hold
20,200
– – ﹤0.01% 2061
2025
Q2 		$179K Hold
20,200
– – ﹤0.01% 2001
2025
Q1 		$158K Sell
20,200
-8,500
-30% -$71.2K ﹤0.01% 1856
2024
Q4 		$302K Buy
28,700
+8,000
+39% +$97.2K ﹤0.01% 1790
2024
Q3 		$271K Hold
20,700
– – ﹤0.01% 1732
2024
Q2 		$291K Hold
20,700
– – ﹤0.01% 1548
2024
Q1 		$350K Buy
+20,700
New +$308K ﹤0.01% 1739

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Point72 Asset Management's AVDL Position: Q1 2026 in Review

Point72 Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 279,525 shares — an estimated $6.02M sold.

Point72 Asset Management first reported a position in AVDL in Q1 2015 and held it in 11 quarters. The position peaked at $11.1M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Point72 Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 279,525 Avadel Pharmaceuticals shares in Q1 2026, an estimated $6.02M.
  • Point72 Asset Management first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 11 quarters.
  • Point72 Asset Management's Avadel Pharmaceuticals position peaked at $11.1M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.